Transdermaalse manustamisega östradiooli sisaldavate ravimite Lenzetto ja Divigeli pikaajalised tarneraskused
Safety Classified by Officially
Müügiloa hoidja Gedeon Richter Plc. teavitas ravimi Lenzetto 1,53 mg/annus transdermaalse sprei, lahuse tarneraskusest eeldatava lõpuga aprillis 2027. Müügiloa hoidja Orion Corporation on teavitas Divigel 1 mg/g transdermaalse geeli tarneraskusest, mis kestab eeldatavasti veebruari alguseni 2027.
Source: State Agency of Medicines (Ravimiamet).
Read the original at the source: https://ravimiamet.ee/uudised/transdermaalse-manustamisega-ostradiooli-sisaldavate-ravimite-lenzetto-ja-divigeli
Officially imported this from State Agency of Medicines (Ravimiamet)’s own source. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- State Agency of Medicines (Ravimiamet) — imported from official source
- Official source
- https://www.ravimiamet.ee/rss-feeds/rss.xml RSS
- Imported
- October 21, 2026 06:33
- Versions
- 1 recorded
- Identity
-
3747 at https://www.ravimiamet.ee/